Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 29, 2025
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2025
Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2025
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2025
Lead Product(s) : Levornidazole Disodium Phosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : Levornidazole Disodium Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2024
Lead Product(s) : Zhengyuan
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Recipient : Qiang Fu
Deal Size : Inapplicable
Deal Type : Inapplicable
Cancer-related Fatigue in Patients With Breast Cancer Treatment With Zhengyuan Capsules
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 24, 2024
Lead Product(s) : Zhengyuan
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Recipient : Qiang Fu
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tunodafil HCl
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the Interaction of Tunodafil Hydrochloride Tablets and Alcohol
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 04, 2023
Lead Product(s) : Tunodafil HCl
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Harbin Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2021
Lead Product(s) : Dexmedetomidine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Harbin Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership
Details : Alvotech and Alvotech & CCHT Biopharmaceutical Co., Ltd will be jointly responsible for the development, registration, and supply of their biosimilars in China, while Yangtze River Pharmaceutical will exclusively commercialize the biosimilar candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 24, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Alvotech
Deal Size : Undisclosed
Deal Type : Partnership